Comparing the current results to its competitors, Mira Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.91 %, recorded in the same quarter.
Mira Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 39.99 %
Mira Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in therapeutic areas such as neuropathic pain, inflammatory pain, obesity, and nicotine dependence. It faces competition from numerous pharmaceutical and biotechnology companies, many of which have greater financial, technical, and commercial resources. The company relies on patents, trade secrets, proprietary know-how, and ongoing innovation to maintain its competitive position. However, it acknowledges that trade secrets may become known or independently developed by competitors. The company has a pending provisional patent application for MIRA-55 but currently holds no patent protection for it, which may affect its competitive standing.
Centessa Pharmaceuticals Plc operates as a biopharmaceutical company that focuses on the discovery and development of innovative medicines. Their business model centers around leveraging a decentralized approach, with multiple subsidiary companies working autonomously to accelerate the research and development of potential therapeutics across various disease areas. By bringing together diverse expertise and resources, Centessa aims to efficiently advance breakthrough therapies and deliver impactful solutions to patients in need.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Cytokinetics Incorporated is a biopharmaceutical company with a business model centered around the discovery and development of novel muscle activators. They strive to improve the lives of patients with debilitating diseases by focusing on the development of potentially life-changing therapies. Cytokinetics aims to achieve commercial success by leveraging its expertise in muscle biology and utilizing strategic collaborations to bring their innovative therapies to market.
Sources:
Mira Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mira Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
